ArticleThe journal of headache and pain2026
Impact of semaglutide introduction on the use of triptans: an interrupted-time series.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests that glucagon-like peptide-1 receptor agonist (GLP-1RA) may be associated with reduced migraine burden. We aimed to evaluate whether semaglutide for weight management initiation is associated with changes in triptan consumption.
methodsWe conducted a nationwide interrupted time series analysis using Danish health registers. All adults initiating semaglutide between December 2022 and December 2024 were included. The first dispensing date served as the index date, establishing a 24-month baseline and a 12-month follow-up period. The primary outcome was monthly triptan consumption (defined daily doses (DDD)/10,000 individuals). Analyses were conducted for new and prevalent triptan users, and stratified by sex, age group, and prior use of prophylactic antimigraine medication.
findingsDuring the study period, 189,392 individuals initiated semaglutide (68% females, median age 50 years). Before initiation, triptan use increased over time; after initiation, this trend reversed, showing a decline of -13 DDD/month/10,000 (95% CI: -25 to -1.3), corresponding to a 7% relative reduction at 12 months (RR 0.93; 0.88-0.97). This decrease primarily reflected a reduction in DDD consumption among prevalent users (RR 0.86; 0.82-0.90) rather than a change in monthly rates of new users. A sex-specific effect was observed, with female users demonstrating an 8% reduction (RR 0.92; 0.88-0.97) and males showing no statistically significant change. The largest reductions occurred in individuals aged 18-35 years (RR 0.86; 0.78-0.94) and previous users of prophylactic antimigraine medications (RR 0.88; 0.82-0.94).
conclusionsWeight-loss semaglutide initiation was associated with a modest, gradual reduction in triptan use, particularly among females and individuals with history of migraine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.